We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

Compound Mechanism of Action Target Indication Status
Aprocitentan*  Dual endothelin receptor antagonist Resistant hypertension management Advancing to Phase 3
Clazosentan** Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage (aSAH) Advancing to Phase 3
Lucerastat Glucosylceramide synthase inhibitor Fabry disease Phase 3
Nemorexant Dual orexin receptor antagonist Insomnia Phase 3
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 2
Vamorolone*** Dissociative steroid Duchenne muscular dystrophy Phase 2
ACT-246475 P2Y12 receptor antagonist Acute coronary syndrome (ACS) Phase 2
ACT-774312 CRTH2 receptor antagonist Asthma and allergy disorders Phase 1
ACT-519276 GBA2/GCS inhibitor Orphan CNS diseases Phase 1
ACT-539313 Selective orexin 1 receptor antagonist Anxiety Phase 1
ACT-709478 T-type calcium channel blocker Epilepsy Phase 1


* In collaboration with Janssen Biotech to jointly develop and solely commercialize aprocitentan worldwide
** In Japan, market registration trials are being conducted, with results expected in the second half of 2018
*** Idorsia has exclusive option to worldwide rights to ReveraGen’s Vamorolone.

"I enjoy working for a company that is growing and where there is so much to do!"

Manager, Human Resources